Atara Bio Announces Second Quarter 2016 Financial Results and Recent Highlights Aug 08, 2016 8:00am EDT
Atara Bio Doses First Patient in Multi-Center Expanded Access Protocol for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) in EBV-Associated Lymphomas and Lymphoproliferative Disorders Jul 12, 2016 8:00am EDT
Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA) Jun 23, 2016 9:30am EDT
Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate Jun 06, 2016 6:30pm EDT
UPDATE: New Abstract Links -- Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting May 18, 2016 7:25pm EDT
Atara Bio Announces Presentations of Clinical Data from EBV-CTL and STM 434 Product Candidates at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting May 18, 2016 5:00pm EDT
